EURURO Vol. 72 No. 3

398 476

the UK. Mirabegron provides an alternative treatment
option for OAB with the potential to increase treatment
persistence. This is an important consideration for clinicians
when managing chronic conditions, as well as for payers
when considering the economic implications of available
treatments for OAB.
Author contributions: Christopher R. Chapple had full access to all the
data in the study and takes responsibility for the integrity of the data and
the accuracy of the data analysis.
Study concept and design: Chapple, Nazir, Hakimi, Siddiqui, Wagg,
Guelfucci.
Acquisition of data: Nazir, Siddiqui, Guelfucci, Khemiri.
Analysis and interpretation of data: Chapple, Nazir, Hakimi, Fatoye,
Siddiqui, Wagg, Guelfucci, Khemiri, Bowditch.
Drafting of the manuscript: Chapple, Fatoye, Siddiqui, Wagg.
Critical revision of the manuscript for important intellectual content:
Chapple, Nazir, Hakimi, Fatoye, Siddiqui, Wagg, Guelfucci, Khemiri,
Bowditch.
Statistical analysis: Fatoye, Guelfucci, Khemiri.
Obtaining funding: Nazir.
Administrative, technical, or material support: Nazir, Bowditch.
Supervision: Chapple, Nazir.
Other: None.
Financial disclosures: Christopher R. Chapple certifies that all conflicts of
interest, including specific financial interests and relationships and
affiliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/affiliation, grants or funding, consultan-
cies, honoraria, stock ownership or options, expert testimony, royalties,
or patents filed, received, or pending), are the following: Christopher R.
Chapple declares a grant from Astellas; research study fees plus
nonfinancial support from Astellas and Allergan; speaker fees plus
nonfinancial support from Astellas, Allergan, and Boston; and consul-
tancy/advisory fees plus nonfinancial support from Astellas, Allergan,
Medtronic, and Pfizer. Jameel Nazir, Zalmai Hakimi, Sally Bowditch, and
Emad Siddiqui are employed by Astellas. Francis Fatoye declares a grant
from Astellas. Florent Guelfucci and Amine Khemiri are employed by
Creativ-Ceutical, which received a grant from Astellas. Adrian Wagg
declares speaker, research, and consultancy fees from Astellas, Pfizer,
SCA AB, and Duchesnay (Canada).
Funding/Support and role of the sponsor: The study was funded by
Astellas and designed and analysed by Astellas in collaboration with the
authors. Astellas had a role in the design and conduct of the study;
management, analysis, and interpretation of the data; and preparation,
review, and approval of the manuscript. Medical writing support,
provided by Harriet Lamb and Tyrone Daniel from Bioscript Medical, was
funded by Astellas Pharma Inc.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
References
[1]
[2]
[3] National Institute for Health and Care Excellence. The management
of lower urinary tract symptoms in men: NICE guideline CG97.
London, UK: NICE; 2010
[4] National Institute for Health and Care Excellence. The management
of urinary incontinence in women: NICE guideline CG171. London,
UK: NICE; 2013
[5]
[6]
[7]
[8]
[9]
[10]
.
[11]
.
[12]
[13]
.
[14]
[15]
.
[16]
.
[17]
.
[18]
.
[19]
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 3 8 9 – 3 9 9 398